Home ›

Publications

Filters: Author is Baiget, M  [Clear All Filters]
2013
Fernandez-Rozadilla C, Cazier JB, Tomlinson IP, Carvajal-Carmona LG, Palles C, Lamas MJ, et al. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC genomics. 2013;14:55. Abstract
2012
Fernandez-Rozadilla C, Palles C, Carvajal-Carmona L, Peterlongo P, Nici C, Veneroni S, et al. BMP2/BMP4 colorectal cancer susceptibility loci in Northern and Southern European populations. Carcinogenesis. 2012. Abstract
Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. The pharmacogenomics journal. 2012. Abstract
2011
Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British journal of cancer. 2011;105(1):53-7. Abstract
Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. International journal of radiation oncology, biology, physics. 2011;81(5):1319-27. Abstract
2010
Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer science. 2010;101(9):2048-53. Abstract
Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J, et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. Journal of cancer research and clinical oncology. 2010;136(11):1681-9. Abstract
Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast cancer research and treatment. 2010;119(1):33-8. Abstract
Paré L, Paez D, Salazar J, del Rio E, Tizzano E, Marcuello E, et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. British journal of clinical pharmacology. 2010;70(2):268-72. Abstract
2008
Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British journal of cancer. 2008;99(7):1050-5. Abstract
Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(6):1788-96. Abstract
Paré L, Salazar J, del Rio E, Baiget M, Altés A, Marcuello E, et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(20):3468; author reply 3468-9.